SABSSAB Biotherapeutics, Inc.
Earnings
When SAB Biotherapeutics, Inc. reports, what it reported each quarter, and how the stock took the results.
23 quarters. Mar 31, 2021 to Sep 30, 2026. USD.
Next results · Q4 2026Projected
10-K due Mar 26 – Apr 5
No earnings release is on file for this company, so the day is the 10-K’s, projected from its last 6 filings.
- Quarter
- Q4 2026 · Ends about Dec 31, 2026
- 10-K window
- Mar 26 – Apr 5
Read against Q4 2025
The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.
- Revenue
- —
- Revenue, change from a year earlier: Q4 2024 −62.4%, Q3 2024 −100.0%, Q2 2024 +207.7%, Q1 2024 +62.5%
- Net income
- -$16.86M
- Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
- EPS
- —
- EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m
Latest results
- Q3 2026Nov 5, 2026, before the open
- Revenue
- —
- —
- Net income
- -$22.30M
- N/M
- EPS
- -$0.24
- N/M
- Revenue
- —
- —
- Net income
- -$22.49M
- N/M
- EPS
- -$0.28
- N/M
- Revenue
- —
- —
- Net income
- -$18.87M
- N/M
- EPS
- -$0.35
- N/M
- Revenue
- —
- —
- Net income
- -$16.86M
- N/M
- EPS
- —
- —
All quarters
| Period | Ended | Announced | Filed | Lag | Form | Revenue | Δ yoy | EPS dil. | Move | Source trail |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2026 | ||||||||||
| Q3 2026 | Sep 30, 2026 | — | Nov 5, 2026 | 36 d | 10-Q | — | — | -$0.24 | — | |
| Q2 2026 | Jun 30, 2026 | — | Aug 6, 2026 | 37 d | 10-Q | — | — | -$0.28 | +2.7% | |
| Q1 2026 | Mar 31, 2026 | — | May 12, 2026 | 42 d | 10-Q | — | — | -$0.35 | 2.7% | |
| FY 2025 | ||||||||||
| Q4 2025derived | Dec 31, 2025 | — | Mar 9, 2026 | 68 d | 10-K | — | — | — | +6.8% | |
| Q3 2025 | Sep 30, 2025 | — | Nov 14, 2025 | 45 d | 10-Q | — | — | -$0.21 | +3.8% | |
| Q2 2025 | Jun 30, 2025 | — | Aug 7, 2025 | 38 d | 10-Q | — | — | -$1.09 | 0.2% | |
| Q1 2025 | Mar 31, 2025 | — | May 9, 2025 | 39 d | 10-Q | — | — | -$0.56 | +2.3% | |
| FY 2024 | ||||||||||
| Q4 2024derived | Dec 31, 2024 | — | Mar 31, 2025 | 90 d | 10-K | $114.70K | −62.4% | — | 11.7% | |
| Q3 2024 | Sep 30, 2024 | — | Nov 6, 2024 | 37 d | 10-Q | $0.00 | −100.0% | -$1.12 | 15.3% | |
| Q2 2024 | Jun 30, 2024 | — | Aug 8, 2024 | 39 d | 10-Q | $263.14K | +207.7% | -$0.79 | 13.1% | |
| Q1 2024 | Mar 31, 2024 | — | May 20, 2024 | 50 d | 10-Q | $944.58K | +62.5% | -$0.54 | — | |
| FY 2023 | ||||||||||
| Q4 2023derived | Dec 31, 2023 | Mar 29, 2024 · market hours | Mar 29, 2024 | 89 d | 10-K | $305.01K | −85.9% | — | 5.5% | |
| Q3 2023 | Sep 30, 2023 | — | Nov 13, 2023 | 44 d | 10-Q | $1.27M | −64.7% | -$0.97 | 2.2% | |
| Q2 2023 | Jun 30, 2023 | — | Aug 21, 2023 | 52 d | 10-Q | $85.52K | −98.7% | -$1.36 | — | |
| Q1 2023 | Mar 31, 2023 | — | May 15, 2023 | 45 d | 10-Q | $581.10K | −95.1% | -$1.46 | 11.4% | |
| FY 2022 | ||||||||||
| Q4 2022derived | Dec 31, 2022 | Mar 31, 2023 · after-hours | Apr 14, 2023 | 104 d | 10-K | $2.16M | −80.5% | — | — | |
| Q3 2022 | Sep 30, 2022 | — | Nov 14, 2022 | 45 d | 10-Q | $3.59M | −75.5% | -$0.16 | 7.1% | |
| Q2 2022 | Jun 30, 2022 | — | Aug 10, 2022 | 41 d | 10-Q | $6.35M | −65.1% | -$0.11 | 2.6% | |
| Q1 2022 | Mar 31, 2022 | — | May 12, 2022 | 42 d | 10-Q | $11.80M | −30.3% | $0.02 | — | |
| FY 2021 | ||||||||||
| Q4 2021derived | Dec 31, 2021 | — | Mar 29, 2022 | 88 d | 10-K | $11.06M | — | — | +15.6% | |
| Q3 2021 | Sep 30, 2021 | Nov 22, 2021 · pre-market | Nov 22, 2021 | 53 d | 10-Q | $14.68M | — | -$0.16 | — | |
| Q2 2021 | Jun 30, 2021 | — | Aug 9, 2021 | 40 d | 10-Q | $18.21M | — | -$0.11 | — | |
| Q1 2021 | Mar 31, 2021 | — | May 21, 2021 | 51 d | 10-Q | $16.93M | — | $0.05 | — | |
Earlier years, FY 2021 to FY 2023The latest three years
Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Source filings
Provenance
ProvenanceData status and checks
SAB Biotherapeutics, Inc. · CIK 1833214 · Engraved from SEC EDGAR